Design and Construction of a Novel Humanized Single-Chain Variable-Fragment Antibody against the Tumor Necrosis Factor alpha

摘要

The pro-inflammatory cytokine, TNF-?±, which plays a major role in the development and persistence of inflammatory diseases, is the basis for the use of anti-TNF-?± therapies. The neutralization of TNF-?± or blockage of its binding to the corresponding receptor has mainly served as a therapeutic strategy against some diseases. This study aimed to investigate the production of a humanized single chain antibody (scFv) against TNF-?±. Therefore, a murine monoclonal antibody, D2 mAb, was selected for humanizing by the complementarity determining region (CDR)-grafting method. Briefly, the replacement of the CDRs from D2 mAb with the specific human single chain scaffold led to the production of a novel humanized scFv mAb against human TNF-?± (hD2). Cloning of hD2 into a suitable expression vector, pGEX-6P-1, resulted in the expression of a 52-kDa GST-fusion protein in E. coli, mostly in the form of inclusion bodies. The solubilization and refolding of GST-hD2 inclusion bodies was achieved with the addition of 4 M urea and subsequent dialysis to recover the fusion protein in soluble form. Then the soluble GST-hD2 was purified by affinity chromatography through immobilized glutathione. The GST pull-down experiment showed a positive interaction between GST-hD2 and TNF-?± protein. Moreover, the results of an MTT assay showed that the purified GST-hD2 has TNF-?± neutralizing activity (Kd of 1.03 nM) and hence hD2 has the potential to be developed into a therapeutic agent. However, more investigation is needed to elucidate the potential of in vivo TNF-?± neutralizing activity of hD2 in comparison to other anti-TNF-?± antibodies.